Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 25;13:1759720X211016661. doi: 10.1177/1759720X211016661

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2021

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 3. — The use of urate-lowering therapies (ULTs) and their association with kidney function (eGFR, serum creatinine, proteinuria/albuminuria and kidney failure events). (a) ULT versus control: eGFR. (b) ULT versus control: serum creatinine. (c) ULT versus control: 24 h proteinuria or albuminuria. (d) ULT versus control: kidney failure events (number of patients having doubling of serum creatinine or eGFR decline by ⩾50% or ESKD defined as eGFR ⩽ 15 m/min per 1.73 m² or requiring dialysis). (e) ULT versus control: eGFR (⩾1 year): subgroup analysis by each urate-lowering drug. (f) ULT versus control: serum creatinine (⩾1 year): subgroup analysis by each urate-lowering drug.

CI, confidence interval; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; IV, inverse variance; ULT, urate-lowering therapy.